期刊文献+

血液透析对游离肉碱的清除及影响因素的研究 被引量:5

Effect of hemodialysis on clearance of free carnitine and infl uencing factors
下载PDF
导出
摘要 目的 研究维持性血液透析 (MHD)患者血浆游离肉碱 (FC)水平以及透析对FC清除的影响。方法 应用酶法检测MHD组血浆和透析液中FC水平及对照组尿中FC水平。结果 MHD患者透前血浆FC水平明显低于正常人 (P <0 .0 1)。透析后 ,血浆FC水平较透析前下降 70 %。每周MHD患者透析所致的FC丢失量远远超过对照组尿液排出量 (P <0 .0 1)。透析过程中 ,FC在第 1小时清除最多。透析中FC的清除量与血浆FC浓度呈正相关 (R =0 .5 1,P =0 .0 1)。应用不同透析器及其复用对FC的清除无显著差异。结论 透析中丢失是MHD患者肉碱缺乏的重要原因。应用不同透析器及其复用对FC清除无明显影响。 Objective To investigate effect of maintainable hemodialysis (MHD) on clearance of free carnitine(FC) and influencing factors.Method The FC level in plasma, dialysate and urine was determin ed by enzymatic method.Results MHD patients exhibited si gnificantly lower plasma FC levels than normal subjects (P<0.01), an d after hemodialysis, a marked decrease by 70% in plasma FC was observed. The we ekly FC loss into dialysate was much greater than the weekly urinary FC excretio n in the healthy subjects(P<0.01). During a dialysis session, the amount of FC eliminated into dialysate was higher in the first hour. Plasma FC level correlated positively with the value of FC loss into dialysate (r=0.51,P= 0.01). There was no significantly difference of the loss of FC to dialysate whe n patients were treated with different dialyzers or reused dialyzers. Co nclusions Hemodialysis therapy is a main factor causing carnitine defi ciency. There is no significantly difference of the loss of FC to dialysate whe n patients are treated with different dialyzers or reused dialyzers.
作者 王英 王梅
出处 《医师进修杂志》 北大核心 2004年第12期23-25,共3页 Journal of Postgraduates of Medicine
关键词 血液透析 肉碱 复用 hemodialysis carnitine reuse
  • 相关文献

参考文献13

  • 1梅长林,徐洪实,顾书华,陈蕾,宋吉.血液透析病人血浆游离肉碱测定及临床意义[J].中华医学检验杂志,1998,21(6):355-358. 被引量:19
  • 2龚德华,季大玺,谢红浪.高通量透析器复用的研究[J].医学研究生学报,2000,13(5):307-310. 被引量:26
  • 3WANNER C, FORSTNER-WANNER S, ROSSLE C, et al. Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation[J]. Kidney Int, 1987, 22(10):s132-s135.
  • 4BERTOLI M,BATTISTELLA P A,VERGANI LUDOVICA,et al. Carnitine deficiency induced during hemodialysis and hyperlipidemia: affect of replacement therapy[J]. Am J Clin Nutr, 1981,34:1 496-1 500.
  • 5EVANS A M,FAULL R,FORNASINI G,et al. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis[J]. Clin Pharmacol Ther, 2000, 68(3):238-249.
  • 6SAKURAUCHI Y,MATSUMOTO Y,SHINZATO T, et al. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients[J]. Am J Kidney Dis, 1998, 32(2):258-264.
  • 7LESCHKE M, RUMPF K W,EISENHAUER T, et al. Quantitative assessment of carnitine loss during hemodialysis and hemofiltration[J]. Kidney Int, 1983,16(12):S143-S146.
  • 8GOLPER T A,WOLFSON M,AHMAD S,et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects[J]. Kidney Int, 1990,38:904-911.
  • 9MOORTHY A V,ROSENBLUM M,RAJARAM R, et al. A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure[J]. Am J Nephrol, 1983, 3(4):205-208.
  • 10RODRIGUEZ-BENITEZ P,PEREZ-GARCIA R,ARENAS J,et al. L-carnitine in dialysis, more than a commercial affair[J]. Nephrol Dial Tranplant, 2000,15:1 477-1 478.

二级参考文献11

  • 1余颂涛,陈伟.人血内中分子量相关物质的测定方法[J].中华肾脏病杂志,1989,5(3):163-164. 被引量:3
  • 2[10] Ringoir S: An update on uremic toxins[J]. Kidney Int,1997,52(s62):s2-s4.
  • 3[11] Rosemary O,Brian PS,Richard AW,et al. Maintaining blood compartment volume in dialyzers reprocessed with peracetic acid maintains Kt/V but not β2-microglobulin removal[J]. Am J Kid Dis,1997,30(4):501-506.
  • 4[1] Sethi D, Gower PE.β2-microglobulin levels, dialysis arth-ropathy and the effect of dialyzer membrane[J]. Nephrol Dial Transplant,1988,3:768-772.
  • 5[2] Caverle Y,Simon P,Ang KS,et al. Serum β2-microglobulin levels in hemodialysis uremia depending on permeability of dialysis membranes[J]. Kidney Int,1987,31:229(abstrac).
  • 6[3] Maidment J,Peter SJ. The dialysis prescription: reuse[J]. Am J Nephrol,1996,16:52-59.
  • 7[4] Petersen J,Moore RM,Kaczmarek RG,et al. The effects of reprocessing cuprophane and polysulfone dialyzers on β2-microglobulin removal from hemodialysis patients[J]. Am J Kidney Dis,1991,17(2):174-178.
  • 8[5] Diaz RJ,Washburn S,Cauble L,et al. The effects of dialyzers reprocessing on performance and β2-microglobulin removal using polysulfone membranes[J]. Am J Kidney Dis,1993,21(4):405-410.
  • 9[6] Westhuyzen J,Foreman K,Battistutta D,et al. Effect of dialyzer reprocessing with Renalin on serum beta-2-microglobulin and complement activation in hemodialysis patients[J]. Am J Nephrol,1992,12:29-36.
  • 10[7] Kerr PG,Argiles A,Canaud B,et al. The effects of reprocessing high-flux polysulfone dialyzers with peroxyacetic acid on β2-mecroglobulin removal in hemodiafiltration[J]. Am J Kidney Dis,1992,19(5):433-438.

共引文献43

同被引文献9

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部